EKF Diagnostics completes Quotient Diagnostics acquisition

Tuesday, Oct 05 2010 by

EKF Diagnostics, the point of care diagnostics company, reported that they have completed the acquisition of Quotient Diagnostics (as reported 23 September 2010 edition of Weekly Update). Quotient Diagnostics developed two proprietary diabetes (Hb1Ac) point of care diagnostic products which are complementary to EKF's existing products.


Disclaimer:  

This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.


Do you like this Post?
Yes
No
0 thumbs up
0 thumbs down
Share this post with friends



EKF Diagnostics Holdings Plc is focused on the In-Vitro Diagnostic device (IVD) market place. The Company is engaged in the designing, development, manufacture and selling of diagnostic instruments, reagents and certain ancillary products. This activity takes place across various geographical locations which include the United States America, Germany, Poland, Russia, United Kingdom and Ireland. The Company’s segments include the manufacture and sale of medical diagnostic equipment. Other services include the servicing and distribution of third party company products under separate distribution agreements. In March 2014, EKF Diagnostics Holdings PLC acquired Separation Technology Inc. The subsidiaries include: EKF Diagnostics Limited; Quotient Diagnostics Limited; EKF-diagnostic GmbH Germany; Senslab GmbH 2; EKF Diagnostyka Sp.z.o.o. ;EKF Diagnostika ; EKF Diagnostics Inc ; Stanbio Laboratory LP ; Stanbio Life Sciences LP ; EKF Diagnostics Limited, and 360 Genomics Limited. more »

Share Price (AIM)
20p
Change
-1.5  -7.1%
P/E (fwd)
n/a
Yield (fwd)
n/a
Mkt Cap (£m)
88.6



  Is EKF Diagnostics Holdings fundamentally strong or weak? Find out More »


What's your view on this thread? to Comment Now

 
 
You are feeling neutral

Use the £ sign in front of a ticker to turn £VOD into Vodafone PLC

You can track all @StockoChat comments via Twitter